PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (NYSE Amex:LCI), a manufacturer of generic pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has completed its cGMP compliance inspection of Lannett’s wholly owned subsidiary Cody Laboratories, Inc. (Cody), a manufacturer/supplier of bulk active pharmaceutical ingredients (API) and finished dosage form products. The two-week long FDA inspection resulted in two minor 483 observations, neither of which prevents Cody from continuing to manufacture products.
